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6/j.bTreatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) has been traditionally empirical, pri-
marily aiming at ameliorating symptoms or treating complications resulting from the disease. Novel therapies
such as eculizumab result in stabilization of hemoglobin levels and improvement in quality of life, but does not
cure PNH. Nonrandomized studies suggest that long-term remissions are achievable when using myeloabla-
tive or nonmyeloablative/reduced-intensity (NMT/RIC) allogeneic hematopoietic stem cell transplantation
(HSCT) as treatment for PNH. Nevertheless, patients with previous life-threatening complications from
PNH may be more appropriately treated with an NMT/RIC regimen, rather than a myeloablative approach,
because of the increased transplant mortality associated with the latter. The decision to perform an alloge-
neic HSCT (allo-HSCT) should weigh disease prognosis, by incorporating known adverse prognostic factors
such as previous history of thrombosis and/or evolution to pancytopenia, among others, against the risk of
transplant-related complications. Selection of the appropriate candidate and, equally important, the right
time to perform an allo-HCT are important questions that need to be answered in the context of large
prospective randomized trials.
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Paroxysmal nocturnal hemoglobinuria (PNH) is
a rare acquired clonal disorder of the hematopoietic
stem cells caused by a somatic mutation in the phos-
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bmt.2008.12.507on the short arm of the X chromosome [1-6]. Identifi-
cation of the resultant deficiency of GPI-linked pro-
teins in patients with PNH led to the development of
flow-cytometry analytic methods for diagnosing the
disease with more accuracy [7]. Absence of CD55
(known as decay accelerating factor) and/or CD59
(known as the membrane inhibitor of reactive lysis)
by flow-cytometric analysis of peripheral blood stem
cells (PBSCs) is presently the most performed test
when diagnosing PNH [7].
Treatment of patients with PNH had been tradi-
tionally empirical, primarily aiming at ameliorating
symptoms or treating complications resulting from
the disease. Better understanding of the pathogenesis
of PNH is bringing more specific therapies into the
clinical practice that aim at treating the disease rather
than its complications. Eculizumab is a humanized
monoclonal antibody (MAb) that targets the terminal
complement protein C5 [8,9]. Hillmen et al. [9] evalu-
ated the efficacy of eculizumab in a randomized,
double-blinded, placebo-controlled, multicenter in-
ternational phase III clinical trial, showing stabiliza-
tion of hemoglobin levels and, consequently,
improvement in transfusion requirements. Eculizu-
mab has also been shown to improve quality of life,
but does not cure PNH [10].
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cases the disease can persist for many years with man-
ageable symptoms, or even experience spontaneous re-
covery [3,11], whereas in other cases the disease course
may be more aggressive leading to bone marrow fail-
ure, or transforming into more aggressive entities
such as acute myelogenous leukemia (AML) [6,12].
Nonrandomized studies suggest that long-term remis-
sions are achievable in patients with PNH when using
allogeneic hematopietic stem cell transplantation
(allo-HSCT). However, the risk of treatmet-related
mortality (TRM) with hematopoietic cell allografting
is relatively high, particularly when using ablative
doses of total body irradiation (TBI) [13]. This pres-
ents a particular challenge to treating hematologists
in identifying patients who may benefit from allo-
HCT. In this article we provide a comprehensive re-
view of the role of allo-HSCT in patients with PNH
published to date.
Diagnosing PNH
The wide array of clinical manifestations in pa-
tients with PNH poses a significant challenge to treat-
ing physicians, not only in establishing the diagnosis,
but managing the complications of the disease as
well. Acute exacerbations of intravascular hemolysis
and subsequent hemoglobinuria results in anemia
from urinary loss of iron. Also, thrombosis is seen in
over one-third of patients, and is one of the most seri-
ous clinical complications from the disease [3].
The Ham’s test, which relies on the abnormal sen-
sitivity of PNH cells to complement mediated intra-
vascular hemolysis, was the gold standard for
diagnosing PNH in the past [14]. The Ham test and
the sucrose lysis test [15] have been largely replaced
by flow-cytometry, which measures absence of CD55
and/or CD59. Flow-cytometry can identify a small-
size PNH clones, of\5%, not otherwise possible in
complement-dependent methodology [16]. Flow-cy-
tometry targeting both CD55 and CD59 is the pre-
ferred approach to establish the diagnosis of PNH.
Granulocytes and monocytes clones, rather than the
red cell clones, are used for flow cytometric analysis
of PNH [16]. This is because red blood cells of patients
with PNH have a shortened life span because of intra-
vascular hemolysis [16].
Clinical Course of PNH
Recently, de Latour et al. [5] compared clinical out-
comes in 460 patients with various subcategories of
PNHwhere thediseasemanifests either as intravascular
hemolysis without overt marrow failure (classic PNH),
or with predominantmarrow failure (aplastic PNH), or
those cases whose clinical presentation(s) do not fit
within previous categories (intermediate) [5]. Throm-
bosis remains a major complication adversely affectingoutcomes in each of the subgroups [5]. Risk factors as-
sociated with increased thrombogenesis included older
age, thrombosis at presentation, previous transfusions,
and lack of immunosuppressive therapy. Also, develop-
ment of pancytopenia resulted inworse outcomes in pa-
tients presenting with classic PNH, whereas malignant
transformation adversely affected survival in patients
with aplastic and intermediate PNH [5]. The authors
conclude that outcomes among the various subcate-
gories of PNH are similar, despite differing clinical
presentations [5]. These findings support previous re-
ported by Socie et al. [2] showing that occurrence of
thrombosis, evolution to pancytopenia, myelodysplas-
tic syndrome (MDS) or AML, among others, are inde-
pendent factors associated with worse outcome in
patients with PNH.
Nontransplant Therapies for PNH
Treatment of PNH, besides allo-HSCT, is gener-
ally supportive including measures such as red cell
transfusions, anticoagulants, or therapies such as glu-
cocorticoids or eculizumab aiming at controlling he-
molysis. Transfusion of packed red blood cells has
been found to be safe in patients with PNH, circum-
venting the need of washed red cells [7]. The iron de-
ficiency resulting from hemoglobinuria can be treated
with iron supplementation.
Androgen therapy with danazol has been used with
mixed results [8,19]. Administration of glucocorticoids
has also been reported to be useful for ameliorating the
severity of hemolysis. Anticoagulants are indicated for
cases presenting with thrombosis, such as the Budd-
Chiari syndrome, among others. Prophylactic use of
anticoagulants has been advocated for patients with
large clones of PNH (.50% granulocytes) [20]. Ecu-
lizumab is a C5-blocking mAb that has been recently
approved for the treatment of PNH [9,10]. Treatment
with eculizumab is relatively well tolerated, and results
in reduction of intravascular hemolysis, hemoglobin-
uria, and, consequently less need for transfusion, and
overall improvement in the quality of life in patients
with PNH.
Allogeneic HCTas Treatment of PNH
Using a matched-related donor
In1984, Szer et al. [21] reporteda seriesof 4malepa-
tients treated with allogeneic bone marrow transplanta-
tion (allo-BMT) for PNH in aplastic phase. Three
patients received allogeneic BM from amatched-related
donor (MRD), and one from a syngeneic donor. Condi-
tioning regimen consisted of cyclophosphamide (Cy; N
5 2) or Cy plus procarbazine (N5 1), or none (N5 1).
All patients engrafted and remained alive and asymp-
tomatic from their disease at 51 to 144 months from
allograft. Acute graft-versus-host disease (aGVHD)
($grade II) was reported in 1 (25%) patient.
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outcome of PNH, also in the aplastic phase, after
allo-BMT from MRD in 4 patients (female 5 3,
male 5 1) using a preparative regimen of Cy, pro-
carbazine plus antithymocyte globulin (ATG) (N
5 3) or busulfan (Bu), Cy, procarbazine plus ATG
(N 5 1). Complete trilineage engraftment occurred
in all patients. There was no evidence of recurrence
of PNH up to 5 years after allografting. The au-
thors note that eradication of PNH was possible de-
spite using a nonmyeloablative preparative regimen
(Cy, procarbazine plus ATG). This would suggest
that PNH is sensitive to adoptive T cell-
mediated immunity derived through a graft-versus-
PNH effect as later demonstrated by Takahashi
and colleagues [23].
Bemba et al. [24] reported the largest single insti-
tution series of 16 patients (female 5 6, male 5 10),
with amedian age of 28 (9-46) years, with PNH treated
with allo-HCT from MRD over a period of 20 years.
Six of 16 patients were in aplastic phase and the rest
were transfusion dependent. Conditioning regimens
included Cy plus thoracoabdominal irradiation (N 5
8) or Cy plus TBI (N 5 1), or Cy plus other (N 5
7). All patients engrafted. aGVHD ($grade II) oc-
curred in 8 (50%) patients. Three (21%) of 14 patient
who were alive beyond 100 days, from allograft, devel-
oped chronic GVHD (cGVHD). Nine patients were
alive at a median follow-up of 53 (3-169) months.
The 5-year survival rate was 58%.None of the patients
had previous history of thrombosis, suggesting a possi-
ble enrollment bias because thrombosis is known to be
associated with poor outcomes in patients with PNH.
An absolute neutrophil count (ANC) .1.0  109/L
and a hemoglobin level (Hgb) .9.0 g/dL at time of
transplant were associated with a better outcomes
(5-year survival .90%).
A registry study by the International BoneMarrow
Transplant Registry (IBMTR) reported outcome of 57
patients, median age 28 (10-47) years, who received an
allo-BMT for PNH at 31 transplant centers between
1978 and 1995 [25]. Source of hematopoietic cells con-
sisted of MRD (N 5 48), syngeneic (N 5 2), or alter-
native donors (MUD5 6, haploidentical5 1) (N5 7).
The majority of patients received a myeloablative pre-
parative regimen (Bu plus Cy [Bu/Cy] 5 53%; TBI
plus Cy [TBI/Cy] 5 21%). The 2-year probability of
survival for the matched sibling group was 56%. Sur-
vival was significantly better for those patients with
sustained engraftment after allo-BMT (70% versus
10%, P 5 .0003). Two recipients of syngeneic trans-
plants were well and alive at 8 and 12 years posttrans-
plantation. Only 1 (14%) of 7 alternative donor
allograft recipients was alive at the 5-year follow-up.
This suggests that TRM may be more pronounced
in recipients of alternative donor allografts. Nonethe-
less, the study is limited by its retrospective nature andthe relative small sample size. The most common
causes of adverse outcomes were graft failure and in-
fections.
These aforementioned studies suggest that allo-
HSCT is capable of inducing prolonged remissions
in over 50% patients with PNH. The risk of mortality
from allograft appears more pronounced in recipients
of unrelated donor allografts. Several questions remain
unaddressed. (1)What is the most effective preparative
regimen for PNH? (2) What is the preferred regimen
for GVHD prophylaxis? (3) When is the right time
to consider allo-HSCT? (4) What risks factors should
be considered when selecting patients for allograft?
These and other similar studies [26-28] are summa-
rized in Table 1.Allo-HCT using an unrelated donor
Most experience using unrelated donor allograft
for PNH is limited to nonrandomized small series
from single institutions or registry data. A previously
mentioned IBMTR registry study included 6 patients
with PNH who received a MUD allograft [25]. Only
1 (16%) was alive after 5 years of follow-up. Causes
of death included graft-failure, organ failure, intersti-
tial pneumonitis, and cGVHD, among others.
Woodward et al. reported a series of 3 cases of un-
related donor allografts (MUD5 2, mismatched unre-
lated donor (MMUD) 5 1) [29] with ages ranging
from 13 to 20 years of age. All patients had aplastic
phase of disease at time of allografting. Patients re-
ceived T cell-depleted grafts after conditioning with
TBI-based regimens. All patients experienced trans-
plant-related complications, but were alive and disease
free at 30 to 62months after allo-HSCT. Interestingly,
this study suggests a potentially beneficial role for
myeloablation per se, independent of the graft-ver-
sus-PNH effect, as these patients received allografts
devoid of T cells. Other series have also shown ade-
quate engraftment and prolonged disease-free survival
(DFS) after allografting [30].
These suggest that use of alternate donor allografts
is feasible. A selection bias for younger age at time of
allograft appears to be a favorable factor that may
have contributed to the difference in outcomes
amongst the various studies using unrelated donors.NMT/RIC allo-HSCT in PNH
Reducing the intensity of the preparative regimens
could potentially allow broader applicability of allo-
HSCT in patients with PNH, especially those with
more advance age or with associated comorbidities.
Hegenbart et al. [31] reported outcome of 7 adult
patients, median age 34 (25-49) years, who underwent
allo-HSCT from peripheral mobilized stem cells
(MUD 5 5; MRD 5 2) using a regimen of Flu plus
Table 1. Allogeneic MRD Transplants for PNH
Author (Ref) Year Published N
Median (Range) Age
Years Gender M/F
TTT Median
(Range) months Period of allo-HCT
Preparative
Regimen Outcome
Szer et al. [21] 1984 4† 17 (14-23) 4/0 28.5 (5-60) 1971–1979 Cy-based†† TRM 5 0%
Median survival 13
(51-144) months
Antin et al. [22] 1985 4 25 (22-27) 1/3 NA 1980–1985 Cy-based TRM 5 0%
Median survival 30
(1-60) months
Kahawara et al. [27] 1992 9§ 22 (14-38) 5/4 24 (6-180) 1971–1990 Bu/Cy 5 2
Cy-only 5 3
Cy-TBI 5 1
Cy-based 5 1
None 5 2
TRM 5 11%
8 of 9 long-term
survivors with long-
term follow-up
from 2.2 to 19.2
years§§
Bemba et al. [24] 1999 16 28 (9-46) 10/6 23 (1-97) 1978–1997 Cy/TAI 5 8
Cy/TBI 5 1
CY-based 5 7
5-year OS 5 58%
Sasˇo et al. [25] 1999 57* 28 (10-47) 26/31 26 (2-240) 1978–1995 Bu/Cy 5 30
Cy/TBI 5 12
Cy/LI 5 11
Cy-based 5 3
None 5 1
2-year survival 5
56% **
Raiola et al. [26] 2000 7 29 (23-37) 4/3 30 (12-192) 1991–1999 Bu/Cy TRM 5 0%
all alive at median F/
U of 51 (6-103)
months post-allo-
HSCT
Lee et al. [28] 2003 3 28 (21-31) 0/3 46 (15-188) 1999–2001 Bu/Flu/ATG TRM 5 33%
2 patients alive at 31
and 37 months
post-allo-HSCT
N indicates number of patients; TTT, time from diagnosis to transplantation; Cy-based, cyclophosphamide or Cy-PAPAPA, procarbazine, rabbit antith-
ymocyte globulin plus cyclophosphamide; TRM, transplant-related mortality; OS, overall survival; NA, not available; Bu/Cy, busulfan plus cyclophospha-
mide; Cy/TBI, cyclophosphamide and total body irradiation; Cy/TAI, cyclophosphamide and thoraco abdominal irradiation; Cy/ALG, cyclophosphamide
plus antilymphocyte globulin; LI, limited irradiation; Bu/Flu/ATG: busulfan, fludarabine, and antithymocyte globulin.
†One of 4 patients had syngeneic transplant with †† no conditioning chemotherapy.
§Six had HLA-MRD, 2 syngeneic and 1 haploidentical.
§§Only 1 patient who had haplo-identical transplant died at day +35 of first transplant.
*HLA-MRD (N 5 48), syngeneic (N 5 2) and alternative donor (N 5 7).
**For only 48 patients who had HLA-matched transplants.
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(CsA) and mycophenolate mofetil (MMF). All patients
engrafted, with a median T cell chimerism of 77% by
28 days. All patients achieved complete remission of
the disease, but 3 (43%) patients died from trans-
plant-related complications. Four patients remained
alive at 13 to 38 months from allo-HCT. This study
shows that using peripheral mobilized stem cells is
also feasible when performing allografts for PNH;
and that PNH is sensitive to adoptive immunotherapy
after minimal conditioning. The TRM of 43% is par-
ticularly high. One should note that two of the trans-
plant-related deaths occurred in patients with
previous history of thrombosis, emphasizing the im-
portance of patient selection.
Takahashi et al [23] reported a series of 5 patients,
median age 30 (25-35) years, with PNH who were
transplanted with a nonmyeloablative regimen of
Flu/Cy plus ATG using MRD as cell source. All pa-
tients had high-risk features such as transfusion depen-
dency or thrombosis. PHN cells were detected in allpatients at time of engraftment but became undetect-
able by 4 months. All patients were alive and disease
free at 5 to 39 months after transplantation. This study
also shows that PNH can be immunologically eradi-
cated, both in vitro and in vivo, following a non-mye-
loablative transplant. These and other studies [28,32]
are summarized on Table 2.CONCLUSIONS AND RECOMMENDATIONS
Understanding the natural history of PNH is of
paramount importance when deciding about therapeu-
tic interventions for individual patients. A small num-
ber of patients with PNHmay experience spontaneous
remissions and long-term survival from the disease;
this is particularly important to take into account
when considering allo-HSCT for PNH.
Allo-HSCT is a feasible therapeutic intervention
that can result in eradication of PNH. Decision to
perform an allo-HSCT has been usually reserved until
evidence of disease progression, such as development
Table 2. Nonmyeloablative allo-HCT for PNH
Author (Ref)
Year
Published N
Median (Range)
Age Years
Gender
M/F
TTT Median
(Range) Months
Period
of allo-HCT
Preparative
Regimen Outcome
Hegenbart
et al. [31]
2003 MUD 5 5
MRD 5 2
34 (25-49) 3/4 24 (12-59) 1999-2001 Flu/TBI TRM 5 43%
CR 5 100%
4 (57%) patients
alive at 13-38
months after
allograft
Takahashi
et al. [23]
2004 MRD 5 5 30 (25-35) 3/2 23 (15-49) NR Fly/Cy/ATG TRM 5 0%
100% survival at
5-39 months after
allograft
Lee et al. [28] 2003 MMUD 5 2 29, 43 2/0 4 and 116 1999-2001 Bu/Flu/ATG or
Cy/ATG
TRM 5 0%
Both alive at 17 and
30 months after
allograft
Brodsky
et al. [32]
2008 HLA- Haploidentical 5 3 27, 33, and 37 2/1 12, 84, and 180 NR Cy/Flu/TBI TRM 5 33%
One death on
day +8.
2 patients alive at 1
and 4 years after
allograft.
N indicates number of patients; TTT, time from diagnosis to transplantation; MUD, matched-unrelated donor; MRD, matched-related donor; Flu/TBI,
fludarabine and 2 Gy of TBI on day 0; TRM, treatment-related mortality; CR, complete remission; NR, not reported; Flu/Cy, cyclophosphamide,-
fludarabine, and antithymocyte globulin; MMUD, mismatched-unrelated donor; Bu/Flu/ATG, Busulfan, fludarabine, and antithymocyte globulin;
Cy/ATG, cyclophosphamide and antithymocyte globulin; CyFlu/TBI, cyclophosphamide, fludarabine and 2 Gy of TBI on day 1.
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requirements, or development of cytopenias despite
immunosuppressive therapies. In vitro and/in vivo
data suggests that PNH is susceptible to the bona
fide graft-versus-PNH effect [24]. Both myeloablative
and nonmyeloablative regimens appear to yield dura-
ble engraftment and sustained remissions with eradica-
tion of the PNH clone. However, most of the studies
reported herein have limited allo-HCT to relatively
younger patients.
RIC regimens have been generally associated with
lesser transplant-associated morbidity and mortality in
various hematologic malignancies such as chronic
lymphocytic leukemia (CLL) [33] or AML [34], with
reasonable preservation of efficacy. Available data, al-
beit nonrandomized, shows that using an NMT/RIC
regimen is feasible in patients with PNH, especially
those of more advanced age and/or PNH related mor-
bidities who would not be otherwise eligible for a mye-
loablative approach. Younger patients without serious
morbidities could be treated with a myeloablative or
RIC regimens.
Previous history of thrombosis confers worse out-
comes in patients undergoing allo-HCT for PNH
[30]; conversely, other series suggest that patients
with preserved hematopoietic function at transplanta-
tion (ANC .1.0  109/L and Hgb .9.0 g/dL) have
better outcomes postallografting [24]. This is not par-
ticularly surprisingbecause a large series of 220patients
with PNH has shown that occurrence of thrombosis,
evolution to pancytopenia, MDS or AML, age .55
years at diagnosis, requirement of additional therapy,
and thrombocytopenia at diagnosis are independentadverse prognostic factors associated with PNH [2].
Patients with previous life-threatening complications
from PNH may be more appropriately treated with
anNMT/RIC regimen rather than amyeloablative ap-
proach because of increased TRM from the latter [31].
The decision to perform an allo-HSCT should
weigh disease prognosis, by incorporating known ad-
verse prognostic factors [2,5], against the risk of trans-
plant complications. Selection of the appropriate
candidate and, equally important, the right time to
consider an allo-HSCT are important questions that
could only be answered in the context of large prospec-
tive collaborative trials.ACKNOWLEDGMENTS
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